<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1707">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05138939</url>
  </required_header>
  <id_info>
    <org_study_id>1306528</org_study_id>
    <nct_id>NCT05138939</nct_id>
  </id_info>
  <brief_title>Effects of Japanese Red Wines on Vascular Function in Adult Men</brief_title>
  <official_title>Effects of Japanese Red Wines on Vascular Function in Adult Men</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study is to investigate the effects of different types of red&#xD;
      wine on markers of endothelial function and platelet aggregation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Potential participants are provided with information about the study and potential risks.&#xD;
      Once participants decided to participate in the study, they will be scheduled for a health&#xD;
      screening visit which determines eligibility to the study entry. If participants are&#xD;
      eligible, they will be randomized in a three-way crossover study design to receive three&#xD;
      interventions (control, red wine1, and red wine2) with the one-week washout period. On the&#xD;
      study day, participants will be assessed for baseline measurements, provided with the&#xD;
      designated beverage, and followed up for the measurements at 2 and 4 hours after the&#xD;
      consumption.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Three-way crossover randomized controlled trial</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants will be blinded by the type of beverages (control, red wine1, and red wine2).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral Arterial Tonometry (PAT)</measure>
    <time_frame>Baseline</time_frame>
    <description>Endothelial function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peripheral Arterial Tonometry (PAT)</measure>
    <time_frame>2 hours after beverage consumption</time_frame>
    <description>Endothelial function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peripheral Arterial Tonometry (PAT)</measure>
    <time_frame>4 hours after beverage consumption</time_frame>
    <description>Endothelial function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet Aggregation</measure>
    <time_frame>Baseline and 2 and 4 hours after beverage consumption</time_frame>
    <description>Light Transmission Aggregometry</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Vascular Function; Platelet Aggregation</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this group are randomized to receive Isocaloric beverage (a beverage that has similar caloric content to the red wines) as the first intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Red wine A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group are randomized to receive red wine A as the first intervention (can be the younger or older vintage).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Red wine B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group are randomized to receive red wine B as the first intervention (can be the younger or older vintage)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Red wine A</intervention_name>
    <description>8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Red wine A</arm_group_label>
    <arm_group_label>Red wine B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Red wine B</intervention_name>
    <description>8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Red wine A</arm_group_label>
    <arm_group_label>Red wine B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>8 oz (237 ml) of control beverage is a beverage that has similar calories to red wines.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Red wine A</arm_group_label>
    <arm_group_label>Red wine B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male: 50-70 years old&#xD;
&#xD;
          -  Subject is willing and able to comply with the study protocols.&#xD;
&#xD;
          -  Subject is willing to participate in all study procedures&#xD;
&#xD;
          -  BMI 18.5 - 40 kg/m2&#xD;
&#xD;
          -  Weight ≥ 110 pounds&#xD;
&#xD;
          -  Prescription medication if on a 6-month self-reported stable dose&#xD;
&#xD;
          -  Regularly consume alcoholic beverages (2 drinks/week to 2 drinks/day)&#xD;
&#xD;
          -  Non-smokers&#xD;
&#xD;
          -  One standard drink of alcoholic beverages is defined as follow:&#xD;
&#xD;
             12-ounces of beer (5% alcohol content) (~1 regular bottle). 8-ounces of malt liquor&#xD;
             (7% alcohol content) (~1 regular bottle). 5-ounces of wine (12% alcohol content) (~½&#xD;
             glass) 1.5-ounces of 80-proof (40% alcohol content) distilled spirits or liquor (e.g.,&#xD;
             gin, rum, vodka, whiskey) (~ 1 shot)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  BMI ≥ 40 kg/m2&#xD;
&#xD;
          -  Daily use of aspirin or NSAIDs&#xD;
&#xD;
          -  Dislike or allergic to any food, especially wine, grape, and alcohol&#xD;
&#xD;
          -  Vegan, Vegetarians, food faddists, or those consuming a non-traditional diet&#xD;
&#xD;
          -  Alcohol consumption &lt; 2 drinks/week (i.e. 1 bottle of beer, ½ glass of wine, and 1&#xD;
             shot of hard liquor)&#xD;
&#xD;
          -  Alcohol consumption &gt; 2 drinks/ day&#xD;
&#xD;
          -  Fruit consumption ≥ 2 cups/day&#xD;
&#xD;
          -  Vegetable consumption ≥ 3 cups/day&#xD;
&#xD;
          -  Fatty Fish ≥ 3 times/week&#xD;
&#xD;
          -  Coffee/tea ≥ 3 cups/day&#xD;
&#xD;
          -  Dark chocolate ≥ 3 oz/day&#xD;
&#xD;
          -  Self-reported restriction of physical activity due to a chronic health condition&#xD;
&#xD;
          -  Self-reported chronic/routine high intensity exercise&#xD;
&#xD;
          -  Self-reported diabetes&#xD;
&#xD;
          -  Blood pressure ≥ 140/90 mm Hg&#xD;
&#xD;
          -  Self-reported renal or liver disease&#xD;
&#xD;
          -  Self-reported heart disease, which includes cardiovascular events and Stroke&#xD;
&#xD;
          -  Self-reported Cushing's syndrome&#xD;
&#xD;
          -  Self-reported chronic/routine high-intensity exercise&#xD;
&#xD;
          -  Inability to properly place or wear the PAT probes or abnormal measurements on&#xD;
             pre-screening PAT&#xD;
&#xD;
          -  Abnormal Liver or Chemistry panels (laboratory values outside the reference range) if&#xD;
             determined to be clinically significant by the study physician.&#xD;
&#xD;
          -  Self-reported cancer within the past 5 years&#xD;
&#xD;
          -  Self-reported malabsorption&#xD;
&#xD;
          -  Use of multi-vitamin and minerals other than a general formula of vitamins and&#xD;
             minerals that meet the recommended dietary allowance (RDA)&#xD;
&#xD;
          -  Not willing to stop any supplement use, including herbal, plant or botanical, fish&#xD;
             oil, oil supplements a month prior to study enrollment.&#xD;
&#xD;
          -  Indications of substance or alcohol abuse within the last 3 years&#xD;
&#xD;
          -  Current enrollee in a clinical research study.&#xD;
&#xD;
          -  Reactive hyperemia index (RHI) value ≥ 2.8 (measured by PAT at the first study visit)&#xD;
&#xD;
          -  Raynaud's disease, history of bleeding disorder and/or abnormal bleeding, and history&#xD;
             of gastrointestinal ulceration and/or bleeding&#xD;
&#xD;
          -  Under current medical supervision&#xD;
&#xD;
          -  1 ug/ml and 3 ug/ml collagen screening maximal platelet aggregatory response of &lt; 65%.&#xD;
&#xD;
          -  Platelet number or mean platelet values that are outside of the normal reference range&#xD;
             as indicated on a complete blood cell count report from the University of California&#xD;
             Davis Medical Center&#xD;
&#xD;
          -  Current diagnosis of anemia; or a screening hemoglobin and hematocrit that is less&#xD;
             than the normal reference range.Individuals with blood clotting or platelet defect&#xD;
             disorders&#xD;
&#xD;
        The following special populations will be excluded:&#xD;
&#xD;
          -  Individuals who are not yet adults (infants, children, teenagers)&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert M Hackman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nutrition, UC Davis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Prae Charoenwoodhipong, MS</last_name>
    <phone>530-761-6183</phone>
    <email>pcharoen@ucdavis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ragle Human Nutrition Research Center</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jody Randolph</last_name>
      <phone>530-752-7620</phone>
      <email>jmrandolph@ucdavis.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vascular function; platelet aggregation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

